Ceribell Inc(CBLL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
October 8 at 5:46 PM ET (Korea 10/9 06:46)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -1.76 | Insider Own | 33.38% | Shs Outstand | 38.2M | Perf Week | -1.95% |
| Market Cap | 0.89B | Forward P/E | - | EPS next Y | 18.49% | Insider Trans | -4.5% | Shs Float | 25.6M | Perf Month | -5.16% |
| Enterprise Value | 0.78B | PEG | - | EPS next Q | -0.51 | Inst Own | 66.64% | Short Float | 7.11% | Perf Quarter | 18.35% |
| Income | -0.07B | P/S | 8.71 | EPS this Y | -35.12% | Inst Trans | 2.55% | Short Ratio | 4.96 | Perf Half Y | 24.66% |
| Sales | 0.10B | P/B | 6.9 | EPS next 5Y | 2.55% | ROA | -35.29% | Short Interest | 1.82M | Perf YTD | 5.56% |
| Book/sh | 3.36 | P/C | 6.87 | EPS past 3/5Y | -10.19% - | ROE | -43.93% | 52W High | -9.67% ($25.63) | Perf Year | 89.13% |
| Cash/sh | 3.37 | P/FCF | - | Sales past 3/5Y | 50.9% - | ROIC | -44.28% | 52W Low | 113.36% ($10.85) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -28.13% | Gross Margin | 88.9% | Volatility(W/M) | 4.29% 3.87% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 7.66 | Sales Y/Y TTM | 31.7% | Oper. Margin | -68.62% | ATR (14) | 0.92 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 8.66 | EPS Q/Q | -34.77% | Profit Margin | -64.73% | RSI (14) | 44.7 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 9.05 | Sales Q/Q | 32.54% | SMA20 | -4.22% ($24.17) | Beta | 0.92 | Target Price | $28.57 |
| Payout | - | Debt/Eq | 0.17 | Earnings | 2026/8/10 | SMA50 | 0.11% ($23.12) | Rel Volume | 0.66 | Prev Close | $23.48 |
| Employees | 327 | LT Debt/Eq | 0.16 | EPS/Sales Surpr. | -8.23% 3.01% | SMA200 | 13.4% ($20.41) | Avg Volume(3M) | 0.37M | Price | $23.15 |
| IPO | 2024/10/11 | Option/Short | Yes/Yes | Trades | 3508 | Volume | 243,792 | Change | -1.41% |
🧠 Cerveil is a US medical device company developing a portable EEG-based rapid seizure detection solution. Its key differentiator is enabling non-specialists in emergency rooms and intensive care units to quickly measure EEG readings and interpret seizure risk through AI algorithms. The company has established itself as a growth-stage medical device company in the neurodiagnostics field, addressing the accessibility and speed limitations of traditional EEG testing with technology.
Over the past 1 year, on the higher side
10% below its 1-year high.
Traded less than usual That is 66% of its average volume.
CBLL has a sound balance sheet but weak earning power
Of every $100 in sales, $68.62 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -35.1% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $871. Peers typically go for $304.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 66.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #44 of 143 in the industry
Based on market cap of $888M.
BBNX#43 Beta Bionics Inc $940M PER - CBLL#44 Ceribell Inc $888M PER - 
QDEL#45 QuidelOrtho Corp $851M PER - 
SIBN#46 SI-BONE Inc $845M PER - 
AHCO#47 AdaptHealth Corp $827M PER - 
FAQ
What kind of company is CBLL?
CBLL belongs to the Healthcare sector and operates in the Medical Devices industry.
What is the market cap of CBLL?
The market cap of CBLL is approximately $888M, ranking 2,688 within its sector.
What is the 52-week high and low for CBLL?
CBLL has recorded a 52-week high of $25.63 and a low of $10.85.
